Clinical Trials on Malignant Dysphagia in Korea, Republic of

Total 323 results

Mural Oncology, Inc

Recruiting

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6)

Cutaneous Melanoma | Mucosal Melanoma

United States, Australia, Canada, Italy, Korea, Republic of, Spain, Taiwan, United Kingdom
Lucid Diagnostics, Inc.

Recruiting

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC (ESOGUARDBE2)

Barrett Esophagus | Esophageal Adenocarcinoma | Barrett's Esophagus Without Dysplasia | Barretts Esophagus With Dysplasia

United States, Netherlands
Children's Oncology Group
National Cancer Institute (NCI); MedStar Georgetown University Hospital

Active, not recruiting

Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States, Canada
Children's National Research Institute

Recruiting

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

Soft Tissue Sarcoma | Ewing Sarcoma | Bone Metastases | Solid Tumors | Rhabdomyosarcoma | Wilms Tumor | Germ Cell Tumor | Hepatic Tumor | Malignant Epithelial Neoplasm

United States
Northwestern University
National Cancer Institute (NCI); Hackensack Meridian Health; Lombardi Comprehensive...

Completed

Expressive Helping for Stem Cell Transplant Patients

Stem Cell Transplantation | Hematologic Malignancy

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

Carcinoma | Malignant Neoplasm | Surgical Procedure, Unspecified | Health Care Provider

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI)

Recruiting

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

HIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related Malignancy

United States
University of Aarhus
National Cancer Institute (NCI); University of Virginia; University of Cambridge and other collaborators

Active, not recruiting

Biomarkers Predictive for Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Evolvement

Cervical Intraepithelial Neoplasia Grade 2 (CIN2)

Denmark
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Non-small Cell Lung Cancer | Pleural Mesothelioma

Chile, Korea, Republic of, Japan, Poland, Spain, United States, Argentina, Australia, France, Italy, Taiwan
University of North Carolina, Chapel Hill
Johns Hopkins University; PENTAX of America, Inc.

Recruiting

Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE) (NO FEAR-BE)

Barrett Esophagus | Intestinal Metaplasia | Esophageal Dysplasia

United States
Children's National Research Institute

Recruiting

International Rare Brain Tumor Registry (IRBTR)

Astroblastoma | BCOR ITD Sarcoma | CNS Sarcoma | Unclassified Tumor, Malignant

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)

Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Neoplasms by Site | Renal Cell Carcinoma | Cancer | Solid Tumor | Anaplastic Large Cell Lymphoma | Neuroblastoma | Malignant Neoplasm | Haematological Malignancy

United Kingdom
Christoph Hornik
National Heart, Lung, and Blood Institute (NHLBI); University of North Carolina...

Recruiting

Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia (SILDI-SAFE)

Bronchopulmonary Dysplasia of Newborn

United States
Baylor College of Medicine

Completed

Intrathecal Mafosfamide

Malignant Meningeal Neoplasms

United States
Mid-Atlantic Oncology Program
Cancer Biotherapy Research Group

Completed

Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors

Lung Cancer | Gastrointestinal Carcinoid Tumor

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma

United States
Phio Pharmaceuticals Inc.
Prosoft Clinical

Recruiting

Intratumoral PH-762 for Cutaneous Carcinoma

Squamous Cell Carcinoma of the Skin | Malignant Melanoma of Skin | Merkel Cell Carcinoma of Skin

United States
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
University Children's Hospital Tuebingen
European Union

Completed

Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia (NEuroSIS)

Bronchopulmonary Dysplasia

Finland, Belgium, Czech Republic, France, Germany, Israel, Italy, Netherlands
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE)

Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Colorectal Neoplasms | Endometrial Neoplasms | Malignant Neoplasm | Malignancy

United Kingdom
St. Jude Children's Research Hospital
Pfizer; Ipsen

Active, not recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Peripheral Primitive Neuroectodermal Tumor | Recurrent Rhabdoid Tumor | Recurrent... and other conditions

United States, Canada
National Cancer Institute (NCI)

Recruiting

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Recurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Refractory Diffuse Intrinsic Pontine...

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Childhood Solid Neoplasm

United States
St. Jude Children's Research Hospital
Millennium Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.

Active, not recruiting

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT)

Malignant Rhabdoid Tumor | Atypical Teratoid Rhabdoid Tumor

United States
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Sarcoma Alliance for Research through Collaboration
United States Department of Defense; Synta Pharmaceuticals Corp.

Completed

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Sarcoma | Malignant Peripheral Nerve Sheath Tumors (MPNST)

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Capecitabine in Treating Patients With Malignant Mesothelioma

Malignant Mesothelioma

United States
Sabine Mueller, MD, PhD
Pacific Pediatric Neuro-Oncology Consortium

Recruiting

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Glioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III Glioma

United States, Australia, Israel, Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Malignant Mesothelioma

United States
Genmab
BioNTech SE

Recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Melanoma | Malignant Solid Tumor | Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Colorectal Cancer (CRC)

United States, Taiwan, Spain, Israel, Korea, Republic of, France, Italy, Denmark, Germany, United Kingdom, Georgia, Moldova, Republic of
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Childhood Solid Neoplasm

United States
Boston Children's Hospital
FDA Office of Orphan Products Development

Active, not recruiting

Abatacept as GVHD Prophylaxis Phase 2

Graft vs Host Disease | Malignancy

United States, Canada
University Hospital Ostrava

Completed

Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions

Carcinoma in Situ | Hoarseness | Recurrent Respiratory Papillomatosis | Chronic Inflammation of Hypopharynx | Macroscopic Laryngeal Lesions | Histological Confirmation of Dysplasia | Invasive Carcinoma of Larynx | Invasive Carcinoma of Hypo Pharynx

Czech Republic
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Unspecified Childhood Solid Tumor, Protocol Specific | Neoplasm of Uncertain Malignant Potential

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Deep Vein Thrombosis | Pulmonary Embolism | Metastatic Malignant Solid Neoplasm | Cerebral Vein Thrombosis | Splanchnic Vein Thrombosis

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
Children's Oncology Group
National Cancer Institute (NCI); Incuron LLC

Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Metastatic Malignant Neoplasm in the Central... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Radiation... and other collaborators

Completed

Talc in Treating Patients With Malignant Pleural Effusion

Metastatic Cancer

United States, Canada
Vapotherm, Inc.
Seattle Children's Hospital; University of Utah; Children's National Research...

Terminated

Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants (MODERATION Neo)

Bronchopulmonary Dysplasia | Neonatal Respiratory Distress | Oxygen Saturation | Infant, Premature

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

Malignant Mesothelioma

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Malignant Melanoma

United States, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Korea, Republic of, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Testicular Yolk Sac Tumor | Recurrent Ovarian Germ Cell Tumor | Recurrent Childhood Malignant Germ Cell Tumor | Recurrent Malignant Testicular Germ Cell Tumor | Childhood Extracranial Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular Germ Cell Tumor | Ovarian... and other conditions

United States, Canada, Australia, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With Metastatic Melanoma

Malignant Melanoma

Canada, Spain, United Kingdom, Hungary, Australia, Austria, Belgium, Ecuador, Estonia, Finland, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Slovenia, Sweden, Turkey, Brazil, India, Germany, Bosnia and Herzegovina and more
Bayer
ImmunoGen and MorphoSys

Completed

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Mesothelioma

Belgium, France, United States, Canada, Spain, Turkey, United Kingdom, Australia, Finland, Italy, Poland, Korea, Republic of, Netherlands, Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Soft Tissues | Metastatic Malignant Neoplasm in the Viscera and other conditions

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Malignant Glioma | WHO Grade 3 Glioma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Central Nervous System Neoplasm | Recurrent Brain Neoplasm | Recurrent Childhood...

United States
Bryan Schneider, MD
Hoosier Cancer Research Network; Walther Cancer Institute; Vera Bradley Foundation... and other collaborators

Completed

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Breast Cancer | Malignant Neoplasm of Breast

United States
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Glioblastoma | WHO Grade 3 Glioma | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Glioma | Recurrent Cholangiocarcinoma | WHO Grade 2 Glioma

United States
Brynn Chappell
The Christie NHS Foundation Trust

Terminated

PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma (PIT)

Mesothelioma

United Kingdom

Clinical Trials on Malignant Dysphagia in Korea, Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations